Placebo is identical to IMP but with no active substance
Sponsors
Immunovant Sciences GmbH
Conditions
ACPA-Positive Rheumatoid ArthritisGeneralized Myasthenia GravisPrimary Sjogren’s Disease
Phase 2
A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult-to-Treat, ACPA-Positive Rheumatoid Arthritis
Active, not recruitingCTIS2024-515973-82-00
Start: 2025-06-23Target: 168Updated: 2026-01-27
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity
RecruitingCTIS2025-520831-18-00
Start: 2025-12-12Target: 72Updated: 2025-12-02